Illumina Ventures is an independently managed venture capital firm focused on early-stage companies pioneering new applications of genomics and precision medicine. The firm invests in life science tools, clinical diagnostics, therapeutics, and other opportunities to improve human health, and operates in strategic partnership with Illumina, Inc., which provides the majority of its capital.
57% of their portfolio is in Biotech & Life Sciences. Deal activity increased 33% year-over-year (4 deals in the last 12 months). Average disclosed round size is $49.5M (across 48 rounds with reported amounts).
Portfolio
46
Fund Size
$325M
Top Stage
Series B
Last 12 Mo
2
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
56 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Precede Biosciences | Series B | $63.5M | Jan 2026 |
 MyOme, Inc. | Unknown | — | Dec 2025 |
 NuCicer | Series A | $11.5M | Jul 2025 |
 Arima Genomics | Series C | $22M | Jun 2025 |
| AArima Genomics | Series C | $22M | Jun 2025 |
 Pillar Biosciences | Series B | $34.5M | May 2025 |
 Human Longevity | Series B | $39.8M | Aug 2024 |
 Predicta Biosciences | Seed | $5.2M | Jul 2024 |
 Attovia Therapeutics | Series B | $105M | May 2024 |
 Actym Therapeutics | Series A | $59.5M | Oct 2023 |
| Precede Biosciences | Series A | $57M | Oct 2023 |
 Lightcast Discovery | Series B | $49M | Aug 2023 |
 Lightcast | Unknown | $38M | Aug 2023 |
 Pluton Biosciences | Series A | $16.5M | May 2023 |
 Mantra Bio | Series A | $9M | Jan 2023 |
 Broken String Biosciences | Series A | $15M | Jan 2023 |
| BBroken String | Series A | $15M | Jan 2023 |
 Protillion Biosciences | Series A | $18M | Dec 2022 |
| DDelfi Diagnostics, Inc. | Series B | — | Jul 2022 |
 Delfi | Series B | — | Jul 2022 |
 Volta Labs | Series A | $20M | Mar 2022 |
 Sherlock Biosciences | Series B | $80M | Mar 2022 |
| Delfi | Series B | $225M | Jan 2022 |
| AArima Genomics | Series B | $7M | Jan 2022 |
 Arbor Biotechnologies | Series B | $215M | Nov 2021 |
Page 1 of 3
Top Co-Investors
ARCH Venture Partners8 shared
Menlo Ventures7 shared
Samsara BioCapital7 shared
Osage University Partners6 shared
Northpond Ventures6 shared
AV8 Ventures6 shared
Windham Capital Partners6 shared
T. Rowe Price5 shared
Hemisphere Ventures4 shared
Agilent Technologies4 shared
M Ventures4 shared
Cowen Healthcare Investments4 shared
OrbiMed4 shared
Foresite Capital4 shared
Rock Springs Capital4 shared
Alexandria Venture Investments3 shared
+ND Capital3 shared
Casdin Capital3 shared
Warburg Pincus LLC3 shared
DFJ Growth3 shared
Last updated: 7 September 2026